Company news
Johnson & Johnson news in 2026
Johnson & Johnson's news releases, calls and decks from 2026, newest first.
John Slump Launches Metis MedTech Following Atraverse Medical Acquisition by Johnson & Johnson
May 28, 2026
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
May 27, 2026
Johnson & Johnson: DePuy Synthes Enters Exclusive U.S., Canada and Australia Distribution Agreement for CGBIO’s NOVOSIS
May 26, 2026
DePuy Synthes Announces Agreement to Acquire Miniature Radiofrequency Tracking Technology Across its Joint Reconstruction Portfolio
May 26, 2026
Johnson & Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health - Abu Dhabi
May 21, 2026
Johnson & Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health - Abu Dhabi
May 21, 2026
Rutgers Business School propels graduating student into Johnson & Johnson leadership program
May 18, 2026
Johnson & Johnson Launches 'Gut Tunnel' Experience in Singapore to Highlight the Importance of Endoscopic Remission in IBD
May 17, 2026
TREMFYA Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan
May 15, 2026
Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter
May 12, 2026
Talvey (Johnson & Johnson: talquetamab-tgvs) Market Research Report 2026: Epidemiology, Pipeline Analysis, Insights & Forecasts, 2020-2025, 2025-2030F, 2035F
May 11, 2026
Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP
May 11, 2026
Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission
May 7, 2026
Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease
May 5, 2026
Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease
May 5, 2026
Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System
May 5, 2026
CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis
May 4, 2026
Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations
April 30, 2026
FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)
April 27, 2026
FDA approves CAPLYTA® (lumateperone) sNDA with robust new data supporting reduced risk of relapse in schizophrenia
April 27, 2026
Viz.ai Announces Strategic Collaboration to Expand Access to AI-Powered Subdural Hemorrhage Care
April 23, 2026
IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)
April 22, 2026
Johnson & Johnson Announces CE Mark Approval for the New ETHICON™ 4000 Stapler
April 22, 2026
[Latest] Global Surgical Drill Bits Market Size/Share Worth USD 540 Million by 2035 at a 5.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
April 21, 2026
National Advertising Division Finds Certain ACUVUE® Oasys Max Claim Supported; Recommends Modification or Discontinuation of Others
April 20, 2026
MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
April 16, 2026
Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%
April 14, 2026
Johnson & Johnson reports Q1 2026 results, raises 2026 outlook
April 14, 2026
Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision
April 10, 2026
Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe
April 7, 2026
ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis
March 28, 2026
Johnson & Johnson’s DARZALEX® (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers
March 27, 2026
Global Baby Powder Market to Reach USD 2.0 billion by 2036 at 5% CAGR, India & Johnson & Johnson Lead Growth
March 26, 2026
FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
March 18, 2026
Johnson & Johnson Drives Innovation in Pulsed Field Ablation with Peru Launch
March 16, 2026
Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer
March 13, 2026
Rybrevant (Johnson & Johnson) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
March 13, 2026
Zabdeno (Johnson & Johnson) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
March 13, 2026
Tecvayli (Johnson & Johnson) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
March 13, 2026
Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients
March 12, 2026
Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line
March 5, 2026
Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)
March 3, 2026
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
March 2, 2026
Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer
February 26, 2026
Johnson & Johnson Enterprise Technology Analysis Report 2025: Accelerators, Digital Strategies, Innovation Programs, Incubators, Technology Initiatives, Partnerships, Investment & Acquisition
February 25, 2026
Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)
February 24, 2026
Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer
February 23, 2026
TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years
February 21, 2026
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer
February 19, 2026
Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania
February 18, 2026
Calls in 2026
Decks in 2026
- Q3 2026 Earnings Presentation
Earnings · 27 slides · Oct 13, 2026
- Q2 2026 Earnings Presentation
Earnings · 24 slides · Jul 15, 2026
- Q1 2026 Earnings Presentation
Earnings · 28 slides · Apr 14, 2026
- Q4 2025 Earnings Presentation
Earnings · 33 slides · Jan 21, 2026